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Abstract
Background:  The Pro12Ala Single Nucleotide Polymorphism (SNP) of the Peroxisome
Proliferator-Activated  Receptor gamma 2 (PPAR-gamma 2) has been associated with insulin
resistance and type 2 diabetes (T2D) and also inconsistently with obesity. The aim of this study was
to evaluate the impact of this SNP with regards to T2D and childhood and adult obesity in the
French Caucasian population.
Methods: We conducted three independent case/control studies encompassing 2126 cases and
1124 controls.
Results: We found a significant association between PPAR-gamma 2 Pro12Ala SNP and T2D (p =
0.04, OR = 1.37), which was stronger when the T2D cohort was stratified according to the obesity
status (p = 0.03, OR = 1.81 in obese T2D subjects). In contrast, there was no association between
the Pro12Ala SNP and childhood and adulthood obesity. In normal glucose tolerant obese adults
(but not in lean subjects), the Pro12 allele was associated with a significant increase in fasting insulin
levels (p = 0.01), and in insulin resistance estimated by the Homeostasis Model Assessment of
Insulin Resistance (HOMA-IR) (p = 0.003), after adjustment for age, gender and BMI. We didn't
detect evidence for an interaction effect between the Pro12Ala SNP and the obesity status with
respect to the HOMA-IR index in normal glucose tolerant children, but we found a borderline
interaction (p = 0.06) in normal glucose tolerant adults.
Conclusion:  Our results showed that the Pro12Ala polymorphism is not associated with
childhood or adult obesity in the French Caucasian population. In contrast, we confirm a
contribution of the PPAR-gamma 2 Pro12 allele in the genetic risk forT2D, especially in obese
subjects, where this allele worsens insulin resistanceand increases fasting insulin levels.
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Background
Insulin resistance is associated with obesity especially
when centrally distributed [1,2]. The connection between
increased adiposity and insulin resistance is still poorly
understood, although recent evidence has suggested that
adipose tissue-released cytokines like adiponectin, resis-
tin, leptin and Tumour Necrosis Factor-Alpha (TNF
alpha) may be contributory factors [3-6]. In this context,
the activation of the adipocyte expressed nuclear receptor
PPAR-γ2, by the new insulin-sensitising drugs thiazolidin-
ediones [7,8], was suggested to increase plasma adiponec-
tin levels, which contributed to the promotion of fatty
acid oxidation and insulin sensitivity in muscle and liver
[9,10] and also to the inhibition of the expression of TNF-
α and resistin [4,11-13].
There is a frequent non synonymous (cytosine to gua-
nine) single nucleotide polymorphism (SNP) in PPAR-γ2
exon 2 [14]. This variation results in a Proline to Alanine
substitution at the codon 12, which has been found to
modulate the transcriptional activity of the gene [15,16].
Several studies have reported an association between
Ala12, increased insulin sensitivity and a reduced risk of
type 2 diabetes [17-20] which has been supported by
meta-analysis [17]. However, results assessing the risk of
the Pro12Ala in obesity were controversial [21,22].
We previously studied the effect of this variant in a rather
limited sample of French Caucasians [23] and found no
association between the Pro12Ala and T2D or obesity in
this population. Given the modest impact of the Pro12Ala
in the T2D risk [17], the previous study may have proba-
bly lacked the statistical power for replication. In order to
achieve a definite conclusion about this gene variant and
"diabesity" in French Caucasians, this present study has
analysed large sample sets representative of the condition
and as well as controls (altogether 2126 cases and 1124
controls). We designed three independent case/control
studies to assess the presence of any association between
the Pro12Ala SNP and T2D, childhood obesity or adult-
hood obesity. In addition the putative effect of this SNP
on insulin sensitivity and insulin secretion indexes in nor-
mal glucose tolerant (NGT) lean subjects and in NGT
obese subjects was evaluated, and as well any possible
interaction between the SNP and adiposity on insulin sen-
sitivity, as recently reported in the US population, was
also assessed [24].
Methods
Subjects
The DNA samples were extracted from EDTA whole-blood
samples using Puregene Kit (Gentra, Minneapolis, M N).
Six samples sets were used for association studies and for
analysis of variance of phenotypic traits: Association stud-
ies with childhood obesity were performed using a set of
195 unrelated lean children from the "Fleurbaix-Laventie
Ville Santé" and a set of 396 unrelated obese children cho-
sen from the cohort of 554 obese children available. The
pool of obese children used in association studies was
constituted by a first set of 278 unrelated obese children
collected from 278 pedigrees with at least one obese child
at the CNRS-Institut Pasteur Unit and at the Jeanne de
Flandres Hospital in Lille, a second set of 90 unrelated
obese children recruited at the Children's Hospital, Tou-
louse [25], and a third set of 28 unrelated obese children
recruited through the "Fleurbaix-Laventie Ville Santé"
study. Children with a BMI greater than the 97th percentile
of BMI for age and sex reported on the tables of Rolland-
Cachera  et al. [26] (French general population) were
defined as obese as recommended by the European Child-
hood Obesity Group (ECOG) [27]. From the 376 lean
children available in the Fleurbaix-Laventie study, only
195 unrelated children were included as control, since all
children with at least one obese sibling were excluded.
Adult obesity association studies were performed using
two sets of adult obese patients: the first constituted by
450 moderately obese adults and the second constituted
by 652 morbidly adult obese patients. These individuals
were collected at the Department of Nutrition of the Hôtel
Dieu Hospital in Paris or at the CNRS-Institut Pasteur
Unit in Lille. Obesity status was defined as BMI ≥ 30 in
adults. We used as control group a set of 611 unrelated
non obese and non diabetic subjects recruited at the
CNRS-Institut Pasteur Unit in Lille (N = 345) and through
the "Fleurbaix-Laventie Ville Santé" study (N = 266) [28].
Association studies with T2D were performed using a set
of 628 type 2 diabetic subjects. Diabetic state was
informed by a fasting and/or glucose-tolerance test
according to the WHO 1999 criteria. Patients are part of a
publicity advertised campaign for "200 families to over-
come diabetes", of CNRS-Institut Pasteur de Lille recruit-
ment (N = 365) or recruited at the Sud Francilien Hospital
in Corbeil-Essonnes (N = 263). We used a group of 318
non diabetic unrelated spouses from T2D and obesity
families, aged more than 50 years old with a fasting gly-
caemia less than 5.6 mmol/l and recruited by a multime-
dia campaign at the Institut Pasteur of Lille.
Quantitative traits were calculated using normal glucose
tolerant subjects selected from each of the initial sample
groups previously described (Table 1). Normal Glucose
Tolerance was defined by fasting glycaemia lower than 6.1
mmol/l and by a 2-hour post OGTT glycaemia lower than
7.8 mmol/l, according to the WHO 1999 criteria when
available. For quantitative trait analysis, a set of 362 NGT
lean children, 507 NGT obese adults and 525 NGT obese
children were analysed. The 865 non obese NGT adultsBMC Medical Genetics 2005, 6:11 http://www.biomedcentral.com/1471-2350/6/11
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cohort was constituted by pooling 547 non obese NGT
subjects and 318 non diabetic subjects.
Genotype-BMI interaction effect on insulin resistance was
calculated separately in NGT children and adults. In each
interaction test, obese and lean subjects were pooled
together. The phenotypic characteristics of all the studied
populations are displayed in Table 1.
Clinical parameters
The Body Mass Index (BMI) was calculated as weight (Kg)
divided by height (m) squared. The Z score of BMI was
calculated using Cole's last mean square method [29].
Quantitative measurements of plasma insulin were car-
ried out using double-antibody radio immunoassays.
Serum glucose concentrations were measured using a glu-
cose oxidase procedure. HOMA-IR and HOMA-B were cal-
culated according to Matthews et al [30].
Genotyping
Genotyping of the Pro12Ala of the PPAR gamma 2 gene
was performed using the Taqman Allelic discrimination
(AD) Assay (Applied Biosystem). The Taqman genotyping
reaction was amplified on a GeneAmp PCR system 9600
(95°C for 10 minutes, followed by 40 cycles of 92°C for
15 seconds, and 60°C for 1 minute), and fluorescence was
detected on an ABI Prism 7900 sequence detector
(Applied Biosystem). The mix used in the Taqman exper-
iment contained 2.5 µl of the master mix, 0.25 µl of Prim-
ers, 0.25 µl of water and 2 µl of DNA with a concentration
of 10 ng/µl.
Statistical analysis
Statistical analysis were carried out using SPSS 10.0 pro-
gram (SPSS, Chicago, IU, USA). The Pro12Ala variant was
complied with Hardy-Weinberg proportions. Fisher's
exact test was applied to compare allelic frequencies
between case and controls [31]. Quantitative traits were
studied using the general linear model (GLM), taking into
account gender, age, BMI and genotype effect (Pro12Pro
versus  Pro12Ala/Ala12Ala-dominant model). The BMI
quantitative trait was adjusted only by gender and age.
The genotype-BMI and genotype-obesity status interac-
tion effects on insulin resistance were also tested using a
GLM procedure. HOMA-IR was the dependant variable.
Age, gender, BMI (or obesity status), and Pro12Ala poly-
morphism were the explicative factors. A term of interac-
tion BMI*Pro12Ala, or obesity status*Pro12Ala was
introduced. The Z score of BMI was used in analyses
including obese children.
Results
Phenotypic characteristics of the studied populations
Phenotypic characteristics of the six populations are
shown in Table 1. Compared to lean children, obese chil-
dren have higher fasting glycaemia and fasting insuline-
mia (11.88 UI/l versus 5.77 UI/l, p < 0.001). Obese adult
subjects have higher glycaemia and fasting insulinemia
(16.11 UI/l versus 5.77 UI/l, p < 0.001) than non obese
subjects. T2D subjects have higher BMI and fasting
insulinemia than non diabetic subjects (11.18 UI/l versus
7.40 UI/l, p < 0.001).
Effect of the Pro12Ala SNP on obesity
The genotypic distributions of the Pro12Ala did not sig-
nificantly deviate from the Hardy Weinberg equilibrium
in any of the six groups of subjects.
There was no significant difference in the allelic frequen-
cies between the four analysed sample sets as shown in
Table 2, ruling out any association between this SNP and
Table 1: Phenotypic characteristics of the studied populations.
Phenotypic traits Obese Children Lean Children Obese Adults Non Obese Adults Type II Diabetics Non Diabetic Adults
Sex (M/F) 264/290
N = 554
198/178
N = 376
357/745
N = 1102
234/377
N = 611
353/276
N = 628
123/195
N = 318
Age (years) 10.44 ± 0.16
N = 554
13.61 ± 0.13
N = 376
47.15 ± 0.41
N = 1102
51.04 ± 0.52
N = 611
59.35 ± 0.45
N = 625
62.03 ± 0.66
N = 318
BMI (kg/m2) 28.16 ± 0.27
N = 554
18.14 ± 0.13
N = 365
42.32 ± 0.265
N = 1102
22.95 ± 0.09
N = 604
26.84 ± 0.14
N = 616
25.69 ± 0.30
N = 318
Z score of BMI 4.10 ± 0.06
N = 554
- 0.24 ± 0.05
N = 365
-- - -
Fasting glycaemia (mmol/l) 4.93 ± 0.02
N = 546
4.71 ± 0.02
N = 364
6.73 ± 0.08
N = 1056
5.03 ± 0.24
N = 571
9.45 ± 0.13
N = 611
4.95 ± 0.02
N = 318
Fasting insulinemia (UI/l) 11.88 ± 0.48
N = 491
5.77 ± 0.21
N = 362
16.11 ± 0.40
N = 1003
S.77±0.22
N = 570
11.18 ± 0.57
N = 304
7.40 ± 0.36 
N = 318
Values are expressed as mean ± mean standard error.BMC Medical Genetics 2005, 6:11 http://www.biomedcentral.com/1471-2350/6/11
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severe childhood or adulthood obesity in the French Cau-
casian population.
Effect of the Pro12Ala SNP on T2D
As previously shown in other ethnic groups, the "at risk"
Pro allele was modestly but significantly more frequent in
T2D subjects than in non diabetic controls (0.87 in con-
trol versus 0.90 in T2D subjects, respectively, p = 0.039,
OR = 1.37, see Table 3 and Figure 1). When T2D subjects
were stratified according to their obesity status (defined
by a BMI = 30), the association with T2D was only signif-
icant in the obese diabetic subgroup (p = 0.030) where it
was found to display a rather strong genetic risk (OR =
1.81) than the non obese diabetic subgroup (OR = 1.28, p
= 0.12, Table 3, Figure 1).
Effect of the Pro12Ala SNP on insulin sensitivity and 
secretion indexes in lean normal glucose tolerant (NGT) 
French Caucasians
The effect of the Pro12Ala variant on diabesity associated
quantitative phenotypes was then assessed under a domi-
nant model in the lean NGT controls (865 adults, and 362
children). The Ala allele was not significantly associated
with fasting insulinemia, glycaemia, BMI or Z score of
BMI, HOMA-IR (insulin resistance index) or with HOMA-
B (insulin secretion index) in any of these two sample sets
(Table 4).
Effect of the Pro12Ala SNP on insulin sensitivity and 
secretion in obese NGT French Caucasians
The impact of the Pro12Ala SNP in the cohort of 1032
normal glucose tolerant obese subjects was then evalu-
ated. In the adult subgroup (n = 507), subjects carrying
the "protective" 12Ala allele showed a significant increase
in their insulin sensitivity (p = 0.003), and consistently, a
decrease in fasting insulinemia (p = 0.01) and of glycae-
mia (p = 0.04, see Table 4). In obese children (n = 525),
the same trend was observed although it did not reach sta-
tistical significance. No effect on insulin secretion index
(HOMA-B), Z score of BMI or BMI was found (Table 4).
Interaction between the Pro12Ala SNP and adiposity on 
insulin resistance
The relationship between the Pro12Ala SNP, HOMA-IR
and the Z score of BMI or BMI in NGT children and adults
respectively was evaluated. Thus, we analysed separately
887 lean or obese NGT children and 1372 NGT adults
(obese and lean together). The general linear model
(GLM) analysis taking into account the continuous trait Z
score of BMI or BMI supported the null hypothesis of no
Table 2: Comparison of Genotypic and Allelic Distribution of Pro12Ala polymorphism in obese versus non obese subjects. Case/
Control studies show that the Pro12Ala polymorphism is not associated with childhood or adult obesity in the French Caucasian 
population (p = 0.19, p = 0.92 respectively).
Populations PPAR genotypes Allelic frequencies P-value of allelic 
frequencies
Pro/Pro Pro/Ala Ala/Ala Pro Ala
Obese children (n 
= 396)
304 (76.8%) 84 (21.2%) 8 (2.0%) 0.87 0.13 P = 0.19 OR = 
0.77 CI = [0.52–
1.14]
Lean children (n = 
195)
156 (77.9%) 39 (21.0%) 0 (1.1%) 0.90 0.10
Obese adults (n = 
1102)
857 (77.9%) 231 (21.0%) 12 (1.1%) 0.88 0.12 P = 0.92 OR = 
1.01 CI = [0.81–
1.26]
Non obese adults 
(n = 611)
478 (78.2%) 123 (20.2%) 10 (1.6%) 0.88 0.12
OR: Odd Ratio and CI: Confidence Interval.
Allelic frequency of the Pro12Ala polymorphism in non dia- betic and type 2 diabetic subjects (T2D) stratified according  to obesity status Figure 1
Allelic frequency of the Pro12Ala polymorphism in non dia-
betic and type 2 diabetic subjects (T2D) stratified according 
to obesity status.
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interaction between the Pro12Ala and the corpulence on
HOMA-IR values in both ages (p = 0.59 and p = 0.32, see
figures 2A and 2B). A similar GLM analysis using the obes-
ity status binary trait (BMI ≥ 97th percentile in children
and BMI ≥ 30 kg/m2 in adults) revealed no evidence for
interaction (p = 0.21) in NGT children, but a borderline
interaction effect (p = 0.06) between the Pro12Ala SNP
and the obesity status with respect to the HOMA-IR index
in normal glucose tolerant adults.
Discussion
In the present study, and in contrast to what we have pre-
viously reported [23], T2D subjects were found to possess
a significantly higher frequency of the Pro12 allele risk
than non diabetic controls, thus supporting a role for
PPAR-γ2 in the genetic risk for type 2 diabetes in French
Caucasians. In contrast, no association with severe forms
of obesity was reported in both adults and children con-
firming our previous finding. Interestingly, in the obese
subgroup of diabetics, the Pro12 allele was found to
nearly double the risk for T2D, although it has a weaker
effect in lean individuals. This discrepancy might be due
to an obesity-dependent effect of the "at risk" allele on
insulin sensitivity. Indeed, obese adults carrying the
Pro12Pro genotype were more insulin resistant than sub-
jects carrying at least one Ala12 allele, with a similar trend
seen in obese children, although no such effect was found
in lean controls.
Li et al [24] reported that the detrimental effect of the
Pro12 allele on insulin sensitivity was stronger in adult
subjects with the highest BMI in the white Caucasian
Table 3: Comparison of Genotypic and Allelic Distribution of Pro12Ala polymorphism in diabetic versus non diabetic subjects. Case/
Control studies show the association of the Pro12Ala polymorphism with T2D in the French Caucasian population (p = 0.04). The 
stratification of diabetic subjects on the obesity status shows that the association previously found is rather due to obese T2D 
subgroup (p = 0.03) than non obese T2D subgroup (p = 0.12).
Populations PPAR genotypes Allelic frequencies P-value of allelic frequencies
Pro/Pro Pro/Ala Ala/Ala Pro Ala
T2D patients (n = 628) 511 (81.4%) 113 (18.0%) 4 (0.6%) 0.90 0.10 P = 0.04 OR = 1.37 C.I = [1.02–1.85]
T2D obese patients (n = 114) 98 (86.0%) 15 (13.1%) 1 (0.9%) 0.93 0.07 P = 0.03 OR = 1.81 C.I = [1.05–3.13]
T2D non obese patients (n = 503) 403 (80.1%) 97 (19.3%) 3 (0.6%) 0.90 0.10 P = 0.12 OR = 1.28 C.I = [0.94–1.74]
Non diabetic subjects (n = 318) 246 (77.4%) 63 (19.8%) 9 (2.8%) 0.87 0.13
OR: Odd Ratio and CI: Confidence Interval.
Table 4: Biochemical parameters of subjects according to Pro12Ala genotypes.
Populations Genotypes Fasting 
insulin (UI/l)
Fasting 
glucose 
(mmol/l)
Body Mass 
Index (Kg/m2)
Z score of 
BMI
HOMA-IR HOMA-B
NGT non obese adults (n = 865) P/P = 673 6.28 ± 0.24 4.92 ± 0.02 23.61 ± 0.14 - 1.39 ± 0.05 92.99 ± 3.44
P/A+AA = 192 6.23 ± 0.31 4.94 ± 0.03 24.02 ± 0.26 - 1.38 ± 0.07 95.11 ± 7.19
P-value 0.92 0.65 0.16 - 0.90 0.78
NGT non obese children (n = 362) P/P = 291 5.39 ± 0.17 4.70 ± 0.21 18.12 ± 0.15 - 0.24 ± 0.06 1.13 ± 0.04 95.84 ± 3.47
P/A+AA = 71 6.21 ± 0.42 4.71 ± 0.04 18.19 ± 0.28 - 0.27 ± 0.12 1.315 ± 0.09 111.58 ± 9.62
P-value 0.06 0.67 0.84 0.84 0.06 0.62
NGT obese adults (n = 507) P/P = 397 14.35 ± 0.60 5.30 ± 0.02 40.82 ± 0.42 - 3.41 ± 0.15 171.07 ± 7.60
P/A+AA = 110 11.93 ± 0.72 5.19 ± 0.05 40.08 ± 0.70 - 2.75 ± 0.16 165.89 ± 17.31
P-value 0.01 0.04 0.40 - 0.003 0.76
NGT obese children (n = 525) P/P = 402 12.00 ± 0.59 4.90 ± 0.22 27.92 ± 0.30 4.06 ± 0.06 2.659 ± 0.14 178.71 ± 8.66
P/A+AA = 123 10.77 ± 0.74 4.89 ± 0.42 28.55 ± 0.62 4.20 ± 0.14 2.368 ± 0.16 169.31 ± 16.48
P-value 0.18 0.61 0.33 0.37 0.18 0.37
Data are given as mean ± mean standard error. Quantitative traits are shown according to the Pro12Ala genotypes in healthy and NGT obese 
French populations under a dominant model. Z score of BMI was used rather than BMI in children. Quantitative traits were studied using a general 
linear model procedure, taking into account gender, age, BMI and genotype effect. BMI was adjusted only by gender and age. Z score of BMI was 
compared according to the Pro12Ala genotypes using the T-test. Pro allele is indicated as P and Ala allele as A.BMC Medical Genetics 2005, 6:11 http://www.biomedcentral.com/1471-2350/6/11
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general population, with similar trends observed in chil-
dren. However, in contrast with these data, we did not
find in the entire cohorts of French adults or children for-
mal evidence for an interaction between adiposity (evalu-
ated by the BMI or the Z score of BMI) and the PPAR-γ2
Pro12Ala SNP on the variation of the insulin sensitivity
index. Consistent with our results, Buzzetti et al. also
failed to confirm this interaction in an Italian general pop-
ulation [32]. We then used the obesity status rather than
the continuous trait BMI or the Z score of BMI in the anal-
ysis of interaction effect. Indeed, the BMI range observed
in our samples was bimodal (due to the pooling effect of
non obese and obese individuals) and highly skewed
regarding a population-based cohort, suggesting that the
study of a binary trait could be more relevant in our exper-
imental design. We didn't detect any interaction in NGT
children group (p = 0.21), but a borderline interaction
effect (p = 0.06) between the Pro12Ala SNP and the obese
status with respect to the HOMA-IR index in normal glu-
cose tolerant adults. Our results, according to the hypo-
thesis advanced by Li et al [24], confirmed that an obesity
background could worsen the detrimental effect of the
PPAR-γ2 Pro12 allele on insulin sensitivity in adult sub-
jects, but not in children.
Clément's negative data with T2D in the same ethnic
group [23] may highlight the fact that studies with modest
sample size can fail to detect true associations. Risch et al.
[33] and Lohmueller et al[34] both state that inadequate
power in replication studies may contribute to the large
number of non replications, hence underlining the
importance of working with large enough sized popula-
tions in order to show a modest variant's effect in a multi-
factorial disease context. Indeed, meta-analysis are in line
with our present data [17].
In our T2D population, the frequency of the protective
Ala12 variant was under-represented compared with adult
population controls (0.10 versus 0.13, respectively) but is
very similar with lean children's cohort (0.10 versus 0.10,
respectively). Thus, in French children, the prevalence of
the "at risk" allele is surprisingly higher than in middle-
Interaction between the Pro12Ala SNP and adiposity on HOMA-IR Figure 2
Interaction between the Pro12Ala SNP and adiposity on HOMA-IR. The interaction was tested using a GLM proce-
dure. HOMA-IR was the dependant variable. Age, gender, BMI or obesity status, and Pro12Ala polymorphism were the expli-
cative factors. A term of interaction BMI*Pro12Ala or obesity status*Pro12Ala was introduced. The Z score of BMI was used 
rather than BMI in analyses including obese children. (A) No evidence for interaction was found neither for Z score of 
BMI*Pro12Ala (p = 0.59) nor obesity status*Pro12Ala (p = 0.21) in 887 normal glucose tolerant lean and obese children (p = 
0.58). (B) No evidence for interaction was found for BMI*Pro12Ala (p = 0.32) in 1372 normal glucose tolerant obese and lean 
adults subjects, but a borderline significant interaction was found for obesity status*Pro12Ala (p = 0.06).BMC Medical Genetics 2005, 6:11 http://www.biomedcentral.com/1471-2350/6/11
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aged non diabetic individuals. However, our results con-
firm those recently obtained by Doney et al in a Scottish
cohort [35]. Indeed, they suggested that the protective
effect of Ala12 against T2D and other metabolic diseases
which increase the risk for premature coronary heart dis-
ease, could result in the selective recruitment of elderly Ala
carriers in control populations.
The Ala12 allele resulted in a reduction in the transcrip-
tional activity of PPAR-γ2 [15] and was associated with an
increase of insulin sensitivity. Interestingly, data from
murine models support these findings; Moderate reduc-
tion of PPAR-γ activity in heterozygous PPARγ-deficient
mice prevented adipocyte hypertrophy, increased fatty
acid combustion and decreased lipogenesis, which
resulted in increased insulin sensitivity with regards to
both glucose disposal and suppression of glucose
production [36-38]. Moreover, these mice showed lower
fasting plasma insulin, higher leptin and adiponectin
serum levels [39]. Stumvoll et al. showed that alterations
in the transcriptional activity of the Ala variant in adi-
pocytes could primarily enhance insulin action on sup-
pression of lipolysis, resulting in a decreased release of
free fatty acids (FFAs) [40]. Boden et al. demonstrated that
reduced availability of FFAs would permit muscle to uti-
lize more glucose and the liver to suppress glucose pro-
duction more efficiently upon insulin stimulation [41].
Taken together, these two results can explain the improve-
ment of the insulin sensitivity as a consequence of the Ala
allele.
Conclusion
In summary, we confirm that, in the French Caucasian
population, the PPAR-γ2  12Ala SNP allele confers a
reduced risk for T2D, and decreased obesity-associated
insulin resistance although it was not associated with
childhood or adulthood obesity. In this regard PPAR-γ2
can be considered as a "diabesity" gene.
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